Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 ISIN · CNE100006T44 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,125 across all filing types
Latest filing 2026-05-19 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document is a list of directors and their roles and functions within the board and board committees of PegBio Co., Ltd. It includes details about the board structure and committee memberships. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no other types of filings. This document fits the description of Board/Management Information (MANG), which covers announcements of changes or details about the company's board of directors or senior management. The document is short and focused solely on board composition and roles, confirming it is not a report or announcement of a report but a management/board information disclosure.
2026-05-19 English
(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (3) NON-COMPLIANCE WITH LISTING RULES
Board/Management Information Classification · 100% confidence The document is an announcement from PegBio Co., Ltd. regarding the resignation of an independent non-executive director, the proposed appointment of a new independent non-executive director, and the company's non-compliance with certain listing rules related to board composition and committees. It includes detailed biographical information about the proposed director and discusses compliance with corporate governance codes and listing rules. There are no financial statements, earnings data, or audit results presented. The content focuses on changes in the board of directors and related governance matters. Therefore, this document fits the category of Board/Management Information (MANG).
2026-05-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing (FF301) submitted to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for the month ended 30 April 2026. It details movements in authorised/registered share capital, issued shares, treasury shares, and public float sufficiency confirmation. It is a regulatory compliance report related to share capital and public float requirements under HKEX Listing Rules Chapter 19B. The document does not contain financial statements, management discussion, or earnings data. It is a regulatory filing reporting share capital and share movement information to the exchange, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS). The document length (7552 characters) and content confirm it is a substantive regulatory filing, not a brief announcement or certification letter.
2026-05-06 English
2025 Annual Report
Annual Report Classification · 100% confidence The document is titled '2025 年度報告 ANNUAL REPORT' and contains extensive sections typical of an annual report, including Corporate Information, Management Discussion & Analysis, Directors and Senior Management, Corporate Governance Report, Directors' Report, Environmental, Social and Governance Report, Independent Auditor's Report, and detailed financial statements such as Consolidated Statement of Profit or Loss, Statement of Financial Position, Changes in Equity, Cash Flow Statement, and Notes to Financial Statements. The length is substantial (15,000 characters), indicating a full report rather than a brief announcement. The content includes detailed business review, strategy, R&D progress, and financial data, consistent with a comprehensive annual report. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-28 English
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION BY THE COMPANY
Share Issue/Capital Change Classification · 75% confidence The document is an exchange announcement made under the Listing Rules and Inside Information Provisions regarding the CSRC’s filing notice for the company’s H Share full circulation application. It is not a financial report, earnings release, or management discussion, but rather a regulatory update on the conversion of unlisted shares to H shares and the intended listing of those shares. This constitutes a change in the company’s capital structure. Accordingly, it falls under “Share Issue/Capital Change (SHA).”
2026-04-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 90% confidence The document is the HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules. It provides routine share capital and public float confirmations for the month ended 31 March 2026. It is a compliance filing submitted to the exchange, not an earnings release, management discussion, or capital-raising announcement. It does not announce the publication of another report but is itself a regulatory submission. It therefore falls under the fallback category “Regulatory Filings (RNS).”
2026-04-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.